RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

Reuters

2025/10/16

RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases

RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575166497"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575166497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575166497?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575166497","market":"nz","top_or_hot":-1,"title":"RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with <a href=\"https://laohu8.com/S/SEER\">Seer, Inc.</a>, a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with <a href=\"https://laohu8.com/S/SEER\">Seer, Inc.</a>, a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL1zfMqD:1","article_id":"2575166497","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575166497","pubTimestamp":1760605280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","SEER":"Seer, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","RTGN":"RetinalGeniX Technologies Inc","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4082":"医疗保健设备"},"translate_title":"RetinalGenix Technologies与Seer Bio签约，推进神经退行性全身性和视网膜疾病的早期检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTGN":0.9,"SEER":0.9,"NDAQ":0.9},"content_text":"RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases\n    \n\n        RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix's ultra-high-resolution retinal imaging technology with Seer's proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer's disease, Parkinson's disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}